A phase 3 trial of Celcuity’s pan-PI3K/mTOR inhibitor has hit its primary endpoint, clearing the biotech to file a second ...

Aspirin reduces the risk of colon cancer recurrence after surgery, but only in patients with a specific genetic marker ...

Celcuity (CELC) cautious Buy: gedatolisib upside hinges on Q2 2026 mutant cohort data in 2L HR+/HER2- breast cancer.

TOS-358 is a covalent, pan-mutant, α-specific PI3K inhibitor designed to address key limitations of existing PI3Kα therapies which include ...

The PI3K cell-signaling network has been an important therapeutic target in oncology research for nearly 40 years ago, but the use of PI3K inhibitors in hematologic malignancies has come under ...

After noticing concerning patient survival data across multiple clinical trials, the FDA is losing confidence in the safety profile of the notoriously toxic PI3K inhibitor drug class for blood cancers ...

The enzyme PI3K plays a critical role in cell migration. Scientists have long understood this function. But researchers have recently unveiled that a subunit of this enzyme also has the ability to ...

Although significant progress has been made in the treatment and management of patients with FL, several challenges remain, including the need to develop better prognostic models and markers for ...

Abbreviations: 4EBP1, 4E binding protein 1; BCL-2, B-cell lymphoma 2; EEF2K, eukaryotic elongation factor-2 kinase; EIF4B, eukaryotic translation initiation factor 4B; ERK, extracellular ...